Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price

Confirmatory Trial Seeks To Show Survival Advantage

 
• By Mandy Jackson
Abstract futuristic human lungs
Testing for KRAS G12C mutations is rising but Mirati will push for improvements • Source: Shutterstock

More from New Products

More from Scrip